Donald P Bottaro, PhD

Affiliations: 
1987- Urologic Oncology Branch National Cancer Institute, Rockville, MD, United States 
Area:
cancer biology, cancer genetics, cell and molecular biology
Website:
https://ccr.cancer.gov/urologic-oncology-branch/donald-p-bottaro
Google:
"Donald Bottaro"
Mean distance: (not calculated yet)
 

Children

Sign in to add trainee
Cecilia Florio research assistant 1990-1991 UCSF School of Medicine
Joshua Schindler research assistant 1992-1993 OHSU
Peter J Kim research assistant 1996-1998 UCLA School of Medicine
Juddi Yeh research assistant 1998-1999 Texas A & M College of Medicine
Sarah Choyke research assistant 2004-2005 National Cancer Institute
Benjamin Hoffman research assistant 2006-2007 National Cancer Institute
Haley M Simpson research assistant 2009-2010 National Cancer Institute
Daniel C Rabe research assistant 2009-2011 Harvard Medical School - Massachusetts General Hospital
Kristen Raffensperger research assistant 2010-2012 University of Pittsburg Medical Center
Nelly Tan grad student 2006-2007 Loma Linda University School of Medicine
Cara Wright grad student 2012-2014 University of Pennsylvania Perelman School of Medicine
Vittoria Cioce post-doc 1993-1995 Biomedical Advanced Research Development Authority (BARDA)
Canan Nebigil post-doc 1996-1997 University of Strasbourg, France (Neurotree)
Regina Day post-doc 1994-1998 Uniformed Services University of Health Sciences
Paola Castagnino post-doc 1995-1999 University of Pennsylvania Perelman School of Medicine
Jesus V Soriano post-doc 1998-2001 National Science Foundation
Deborah Pajalunga post-doc 2000-2002 Sapienza University of Rome
Xiaozhen Xie post-doc 2000-2002 US Patent and Trademark Office
Gagani Athauda post-doc 2003-2005 Herbert Wertheim College of Medicine, Florida International University
Benedetta Peruzzi post-doc 2004-2006 Azienda Ospedaliero Universitaria Careggi
Alessio Giubellino post-doc 2003-2010 University of Minnesota Medical School
Deborah R Kaye post-doc 2009-2010 National Cancer Institute
Fabiola Cecchi post-doc 2007-2012 Astra-Zeneca (R&D)
Young H Lee post-doc 2010-2015 Altimmune
Dinuka M. De Silva post-doc 2015-2019 National Cancer Institute (Microtree)
Arpita Roy post-doc 2015-2019 U.S. Food and Drug Administration (FDA)
Molly M. Lee post-doc 2017-2020 U.S. Food and Drug Administration (FDA)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Pahwa R, Dubhashi J, Singh A, et al. (2022) Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Journal of Experimental & Clinical Cancer Research : Cr. 41: 208
Shah MA, Wainberg ZA, Catenacci DVT, et al. (2021) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 16: e0261994
Lee YH, Lee MM, De Silva DM, et al. (2021) Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. Plos One. 16: e0241766
Kummar S, Srivastava AK, Navas T, et al. (2021) Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs
Apolo AB, Nadal R, Tomita Y, et al. (2020) Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. The Lancet. Oncology
Navas T, Kinders RJ, Lawrence SM, et al. (2019) Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Cancer Research
Apolo AB, Mortazavi A, Hu ZI, et al. (2019) Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi). Journal of Clinical Oncology. 37: 4555-4555
Navas T, Srivastava AK, Govindharajulu JP, et al. (2019) Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors. Journal of Clinical Oncology. 37: 3131-3131
Msaouel P, Hong AL, Mullen EA, et al. (2018) Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer
Navas T, Pfister TD, Colantonio S, et al. (2018) Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. Plos One. 13: e0199361
See more...